Live Breaking News & Updates on Ravindrak Gupta

Stay updated with breaking news from Ravindrak gupta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

World Health Organization declares B.1.617, first identified in India, the fourth variant of concern


World Health Organization declares B.1.617, first identified in India, the fourth variant of concern
At their Monday COVID-19 press brief, the World Health Organization (WHO) declared the highly contagious variant first identified in India, classified as B.1.617, as a variant of concern, meaning that it is now considered a global health threat. Dr. Maria Van Kerkhove, the technical lead for the COVID-19 pandemic, explained, “In our consultation with our virus evolution working group, our epidemiology teams, and our lab teams internally, there is some available information to suggest increased transmissibility of B.1.617.”
She added that this variant could also reduce neutralization from antibodies, implying it has the ability to evade immunity to some degree, one of the key reasons it was classified as a variant of concern. The designation is used for those mutations that have been demonstrated to be more contagious, deadly or resistant to the COVID-19 vaccines current ....

United States , United Kingdom , New Delhi , South Africa , South African , Michael Butokiev , Ravindrak Gupta , Maria Van Kerkhove , Sujeet Singh , Tedros Adhanom Ghebreyesus , Shahid Jameel , Narendra Modi , Mariangela Simao , National Center , World Health Organization , Ashoka University In Sonipat , Bharatiya Janata Party , Health Products , West Bengal , Disease Prevention , Ashoka University , Sequencing Consortia , Indian Prime Minister Narendra Modi , Kumbh Mela , Ganges River , South America ,

Indian double mutant variant of Covid-19 less severe for vaccinated: Study


The Indian double mutant variant of coronavirus B.1.617 that has been termed as a variant of concern by the World Health Organization is moderately resistant to antibodies and is highly transmissible but has low severity among those who are vaccinated, a molecular study has said.
The study published by Indian SARS-CoV-2 Genomic Consortia along with the scientists of the Cambridge University in the UK in the bioRxiv, an open access preprint server, “Extensive vaccination will likely protect against moderate to severe disease and will reduce the transmission of B.1.617 given the in vitro neutralisation data we and others have presented.” ....

United Kingdom , Ravindrak Gupta , Oxford Astrazeneca , Cambridge University , University Of Tokyo , World Health Organization , Cambridge Institute For Therapeutic Immunology , Institute Of Genomics , National Centre For Disease , Cambridge Institute , Therapeutic Immunology , Infectious Diseases , National Centre , Disease Control , Integrative Biology , ஒன்றுபட்டது கிஂக்டம் , கேம்பிரிட்ஜ் பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் டோக்கியோ , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , கேம்பிரிட்ஜ் நிறுவனம் க்கு சிகிச்சை நோயெதிர்ப்பு , நிறுவனம் ஆஃப் மரபியல் , தேசிய மையம் க்கு நோய் , கேம்பிரிட்ஜ் நிறுவனம் , சிகிச்சை நோயெதிர்ப்பு , தொற்று நோய்கள் , தேசிய மையம் ,